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Tocopherols (chromanols) and tocopheryl quinones occur natu-
rally in biological membranes. Related 6-hydroxy-chromanones were
observed as byproducts of industrial tocopherol processing. Because
of the extensive use of some tocopherols as food supplements, the aim
of the study was to assess their inhibiting properties at the mam-
malian cytochrome bc1 complex as toxicological and pharmacological
target. The effects of these compounds and low molecular analogues
at the isolated cytochrome bc1 complex from bovine heart were
studied by dual-wavelength photometry, stopped ﬂow photometry,
and low temperature EPR spectroscopy. Our data show that α- and γ-
tocopherols as well as α-tocopheryl quinone required millimolar
concentrations to achieve half inhibition (IC50) of the decylubiquinol:
cytochrome c oxidoreductase activity. In contrast, γ-tocopheryl
quinone and the less lipophilic 6-hydroxy-4,4,7,8-tetramethyl-chro-
man-2-one (TMC2O) exhibited IC50 values of 117±6 and 94±12 µM,
respectively. Stopped ﬂow measurements of the reduction of cyto-
chromes in the isolated cytochrome bc1 complex revealed that TMC2O
preferably inhibited the cytochrome c1 reduction. EPR spectra of the
ascorbate-reduced Rieske iron sulfur protein at 20 K documented a
shift of gz from 2.0288±0.0005 (control) to 2.02240±0.0003 (TMC2O)
indicating a speciﬁc binding of this compound. Besides toxicological
implications for the effect of γ-tocopheryl quinone on the cytochrome
bc1 activity in vivo, our data suggest that synthetic modiﬁcations of
TMC2O could lead to a new class of cytochrome bc1 inhibitors.
doi:10.1016/j.bbabio.2008.05.410
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On the basis of the three-dimensional structures of the bc1
complex in the presence of the inhibitor stigmatellin, it is assumed
that the substrate quinol binding involves the cyt b glutamate residue
E272. However, this residue is not totally conserved during evolution:
in some β and γ-proteobacteria, it is replaced by valine or proline and
another glutamate is conserved and corresponds to H253 in yeast.
Studies of bc1 complexes with E272/H253 mutations will be pre-
sented. Replacement of E272 with apolar residues did not abolish the
bc1 activity, although it slowed down the kinetics of electron transfer.
The Kmvalue for the binding of the substrate quinol was not modiﬁed,
and the EPR data showed that the quinol binding still occurred in the
mutants. Binding of stigmatellin was retained, however mutations
E272P,V induced resistance toward myxothiazol. The pH dependence
of the bc1 activity was not modiﬁed in the absence of the glutamate
E272. Our results suggest that residue E272 may not be involved in
direct substrate binding or in its direct deprotonation. Revertants
were selected with polar residues serine and threonine at position
272. The data lead us to suggest that E272 may be involved in a later
step on the proton exit pathway via the interaction with a water
molecule.
doi:10.1016/j.bbabio.2008.05.411
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Thebc1 complex is a central complex in themitochondrial respiratory
chain. It links the transfer of electrons from ubiquinol (QH2) to
cytochrome c and proton translocation across the inner mitochondrial
membrane. It is widely agreed that the “Q-cycle mechanism” proposed
by Mitchell correctly describes the bc1 complex functioning. It is based
on an unexpected separation of the two electrons coming from the QH2
molecule bound at the Q0 site of the bc1 complex. One electron is
transferred to the iron–sulfur centre (FeS) of the iron sulphur protein
(ISP) and the second to the lower potential heme bL. The electron on
heme bL moves within the cytochrome b to reduce the higher potential
hemebH,which in turn reduces anubiquinone (Q)or a semiquinone (SQ)
at a second ubiquinone binding site Qi. Using a stochastic approach
based on the known spatial structure of bc1 complexes and the kinetic
parameters described by Moser and Dutton, we have demonstrated the
natural emergence of the Q-cycle mechanism and the quasi absence of
short-circuits in the functional dimer of bc1 complex without the
necessity to invoke any additional mechanism. In this poster we studied
the various parameters which inﬂuence the reaction between redox
centers. The natural distances measured on the crystallographic
structures appeared to minimize the short-circuits thus favouring an
energetic “Q-cycle” mechanism.
doi:10.1016/j.bbabio.2008.05.412
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Inhibitors of the mitochondrial respiratory chain enzyme cyto-
chrome bc1 – especially inhibitors targeting the Qo site of the enzyme –
have been developed as anti-microbial agents. They are used in
agriculture to control plant pathogenic fungi and in medicine against
human pathogens, such as the malaria parasite. Unfortunately, the
problem of acquired resistance has rapidly emerged. Resistance is
often linked to mutation within the mitochondrially-encoded cyto-
chrome b that forms the Qo site. To obtain information on the mole-
cular basis of the resistance and of the differential evolution of the
mutations, we used yeast (Saccharomyces cerevisiae) as a model
organism.Wemodiﬁed theQo site of yeast bc1 complex and introduced
variations and resistance mutations found in pathogens. The respira-
tory activity, the sensitivity to inhibitors and the ﬁtness of the yeast
mutants were then analyzed. In particular, we studied the resistance
mutations F129L, G137R and G143A found inmany pathogenic fungi of
important crops.We addressed the question of the impact of structural
variations in theQo site and of variations in the intron/exon structure of
the cytochrome b gene on the evolution of G143A. We also remodeled
S105ABSTRACTS / Biochimica et Biophysica Acta 1777 (2008) S2–S111
